Rejnmark, Lars
Gosmanova, Elvira O.
Khan, Aliya A.
Makita, Noriko
Imanishi, Yasuo
Takeuchi, Yasuhiro
Sprague, Stuart
Shoback, Dolores M.
Kohlmeier, Lynn
Rubin, Mishaela R.
Palermo, Andrea
Schwarz, Peter
Gagnon, Claudia
Tsourdi, Elena
Zhao, Carol
Makara, Michael A.
Ominsky, Michael S.
Lai, Bryant
Ukena, Jenny
Sibley, Christopher T.
Shu, Aimee D. http://orcid.org/0000-0003-1801-5289
Clinical trials referenced in this document:
Documents that mention this clinical trial
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
https://doi.org/10.1007/s12325-024-02843-8
Article History
Received: 30 December 2023
Accepted: 12 March 2024
First Online: 30 April 2024
Declarations
:
: Lars Rejnmark: Research funding from Takeda, Kyowa Kirin International, Ascendis, and Calcilytix; honoraria from Calcilytix Therapeutics; advisory board for Takeda and Amolyt. Elvira Gosmanova: Honoraria from Novo Nordisk and Takeda; advisory board role for Ascendis Pharma and Takeda; travel, accommodations, and expenses from Ascendis Pharma; industry-sponsored grants from AstraZeneca, AbbVie, and Kowa Research Institute. Aliya Khan: Research funding and/or industry grants from Amolyt, Ascendis, Chugai, Radius, and Takeda; honoraria from and advisory board member for Amgen, Alexion, Ascendis, and Takeda; travel, accommodations, and expenses from Ascendis; consulting role for Amgen, Alexion, Amolyt, and Ascendis; speakers bureau participation for Amgen. Noriko Makita: Research funding from Kyowa Kirin. Yasuo Imanishi: speakers bureau for Kyowa Kirin Co., Ltd and Daiichi Sankyo Co., Ltd. Yasuhiro Takeuchi: Honoraria from Chugai Pharmaceutical Co. Ltd; consulting fee from Teijin Pharma; speakers bureau for Amgen Japan. Stuart Sprague: Research funding from Amgen, Amylot, Ascendis, Ardelyx, Frensinius, and OPKO and consultant Amgen, Ardelyx, Bayer, Fresenius, Horizon, OPKO, and Shire. Dolores Shoback: Research/salary funding from Bone Health Tech; research funding from Ascendis. Lynn Kohlmeier: Research funding from Amolyt and Ascendis; speakers bureau, honoraria from Amgen, Radius, and Ascendis; advisory board, consultant for Radius, Alexion, and Ascendis. Mishaela Rubin: Study investigator for Takeda, Ascendis, Amolyt, and Calcilytix; advisory board for Ascendis, speakers bureau for Ascendis; consulting for MBX. Andrea Palermo: Consultant for Theramex, Bruno Farmaceutici, Amgen; research funding from Amgen, Shire, Ascendis; speakers bureau UCB, Amgen; industry grant from Amgen. Peter Schwarz: Stock ownership Novo Nordisk, Genmab. Claudia Gagnon: Advisory board member for Novo Nordisk; honoraria from Amgen; industry grants from Ascendis, Shire, and Takeda. Elena Tsourdi: Honoraria from Amgen, UCB, Takeda, Kyowa Kirin, and Ascendis; advisory board member for Amgen and UCB. Carol Zhao, Michael Makara, Michael Ominsky, Bryant Lai, Jenny Ukena, Christopher Sibley, and Aimee Shu are full-time employees of Ascendis Pharma.
: The protocol was reviewed by the appropriate institutional review boards and independent ethics committees (Supplementary Material Table ). The trial was designed by the sponsor and authors and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as described in the International Conference on Harmonization Guideline E6. All participants provided signed informed consent before treatment initiation.